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Abstract
Background: Treatment of pulmonary sarcoidosis is recommended in case of significant symptoms, impaired or
deteriorating lung function. Evidence-based treatment recommendations are limited and largely based on expert
opinion. Prednisone is currently the first-choice therapy and leads to short-term improvement of lung function.
Unfortunately, prednisone often has side-effects and may be associated with impaired quality of life. Methotrexate
is presently considered second-line therapy, and appears to have fewer side-effects.
Objective: The primary objective of this trial is to investigate the effectiveness and tolerability of methotrexate as
first-line therapy in patients with pulmonary sarcoidosis compared with prednisone. The primary endpoint of this
study will be the change in hospital-measured Forced Vital Capacity (FVC) between baseline and 24 weeks.
Secondary objectives are to gain more insights in response to therapy in individual patients by home spirometry
and patient-reported outcomes. Blood biomarkers will be examined to find predictors of response to therapy,
disease progression and chronicity, and to improve our understanding of the underlying disease mechanism.
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Methods/design: In this prospective, randomized, non-blinded, multi-center, non-inferiority trial, we plan to
randomize 138 treatment-naïve patients with pulmonary sarcoidosis who are about to start treatment. Patients will
be randomized in a 1:1 ratio to receive either prednisone or methotrexate in a predefined schedule for 24 weeks,
after which they will be followed up in regular care for up to 2 years. Regular hospital visits will include pulmonary
function assessment, completion of patient-reported outcomes, and blood withdrawal. Additionally, patients will be
asked to perform weekly home spirometry, and record symptoms and side-effects via a home monitoring
application for 24 weeks.
Discussion: This study will be the first randomized controlled trial comparing first-line treatment of prednisone and
methotrexate and provide valuable data on efficacy, safety, quality of life and biomarkers. If this study confirms the
hypothesis that methotrexate is as effective as prednisone as first-line treatment for sarcoidosis but with fewer side-
effects, this will lead to improvement in care and initiate a change in practice. Furthermore, insights into the im-
munological mechanisms underlying sarcoidosis pathology might reveal new therapeutic targets.
Trial registration: The study was registered on the 19th of March 2020 in the International Clinical Trial Registry,
www.clinicaltrials.gov; ID NCT04314193.
Keywords: Sarcoidosis, Prednisone, Methotrexate, Biomarkers, Quality of life, Home monitoring
Background
Sarcoidosis is a multisystem, granulomatous disorder
of unknown cause, which most commonly affects the
lungs. Patients often have organ-specific symptoms
such as dyspnea and cough, but many patients also
suffer from a wide range of other disabling, non-
specific symptoms including fatigue, stress, anxiety,
depression, small-fiber neuropathy, decreased exercise
tolerance, cognitive impairment, and chronic pain [1,
2]. These symptoms have a major impact on quality of
life (QoL) and social as well as work participation of
sarcoidosis patients [1, 2]. Treatment of pulmonary
sarcoidosis should be considered for patients with sig-
nificant pulmonary symptoms and patients with an
impaired or deteriorating lung function [3, 4]. The
ATS/ERS/WASOG guideline, dating from 1999, rec-
ommends oral corticosteroids as the first-choice ther-
apy for pulmonary sarcoidosis and this is also
reflected in a recent Delphi consensus statement and
current practice [5–7]. These recommendations are
mainly based on expert opinion and limited evidence
from observational studies. Both state that more re-
search is needed to define the best treatment for pa-
tients with pulmonary sarcoidosis [5–7]. Although
corticosteroid treatment leads to short-term improve-
ment of pulmonary function, radiological improve-
ment, and symptom reduction, previous studies have
not conclusively demonstrated a beneficial effect in
preventing disease progression in the long-term [3, 4,
7]. Corticosteroids can have debilitating side-effects,
such as diabetes, osteoporosis, depression and weight
gain [8–10]. Long-term use of corticosteroids is asso-
ciated with impaired QoL [11]. Hence, there is a major
need to find better treatment options for sarcoidosis
with fewer side-effects and less impact on QoL.
Methotrexate is most used as second-line therapy,
when prednisone is ineffective or not tolerated, and ap-
pears to have fewer side-effects [7, 12]. Even though
methotrexate is sometimes used as first-line therapy in
case of (relative) contra-indications for prednisone, no
data on its effectiveness as first-line treatment for pul-
monary sarcoidosis exist. A number of studies evaluated
the efficacy of methotrexate as second-line treatment for
sarcoidosis, and showed that methotrexate had a signifi-
cant steroid-sparing effect and improved pulmonary
function [13–16] . Most commonly reported side-effects
in these studies were gastro-intestinal complaints, head-
ache, general malaise and infections. These side-effects
only led to treatment discontinuation in a minority of
cases. Moreover, according to a sarcoidosis expert sur-
vey, methotrexate seems to be safe and well tolerated
when used for a prolonged period of time [12].
Tailoring of existing therapies and development of new
treatments is also hampered by the incomplete understand-
ing of the pathobiology of sarcoidosis [17]. Biomarkers pre-
dictive of disease behavior and response to therapy are
highly needed to avoid overtreatment with unnecessary
side-effects in some patients and undertreatment with pos-
sible organ damage as a result in others. The ideal bio-
marker is highly sensitive, widely reproducible, rapidly
available and low priced. Unfortunately, none of the cur-
rently used biomarkers in sarcoidosis care fulfills these cri-
teria [18]. Available data indicate a role for specific T-cells,
called Th17.1-cells, and cytokine expression in dendritic
cells (DCs) in predicting disease course [19]. Furthermore,
higher numbers of intermediate and non-classical mono-
cytes at baseline also seem related to response to therapy in
patients treated with infliximab [20] . Further advances in
serum as well as cellular biomarker discovery can provide
more insights into disease mechanisms, disease behavior,
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and response to therapy. Home monitoring of lung func-
tion and patient reported outcomes is a more clinical ap-
proach to assess response to treatment, as this will allow
for more detailed information on treatment effect [8, 21].
Together, this will contribute to personalized treatment of
sarcoidosis.
This paper describes the design of the PREDMETH
study, which will evaluate the efficacy of methotrexate as
first-line treatment for pulmonary sarcoidosis compared
to prednisone, and aims to improve evidence-based
treatment options and quality of life for patients with
sarcoidosis.
Methods/design
Objectives and endpoints
The main objective of this study is to investigate the ef-
fectiveness and tolerability of methotrexate as first-line
therapy in patients with pulmonary sarcoidosis com-
pared with prednisone. The primary endpoint of this
study is the change in hospital-measured Forced Vital
Capacity (FVC) between baseline and 24 weeks. Second-
ary objectives are to gain more insights in response to
therapy in individual patients by home spirometry and
patient reported outcomes. Furthermore, we aim to also
examine blood biomarkers of disease progression and
chronicity, to assess whether response to therapy can be
predicted in individual patients, and to gain more in-
sights into the underlying disease mechanism and poten-
tial new targets for therapy. Table 1 shows the endpoints
of the PREDMETH study.
Design and participants
The PREDMETH study is a prospective, randomized,
non-blinded, multi-center, non-inferiority trial, designed
to compare effectiveness and tolerability of methotrexate
versus prednisone as first-line therapy for pulmonary
sarcoidosis. The study is a joint design of clinicians, sci-
entists and a patient expert panel. In this study, 18 cen-
ters in the Netherlands will participate. The study will
randomize a total of 138 treatment-naïve adult sarcoid-
osis patients, about to start first-line therapy for a pul-
monary indication.
Patients will be informed about the study by their
treating physician. If patients are willing to participate,
written informed consent will be obtained, and patients
will be screened for eligibility. The in- and exclusion cri-
teria are shown in Table 2. If eligible, patients will be
randomized in a 1:1 ratio to receive either prednisone or
methotrexate for 24 weeks, after which they will be
followed up in regular care up to 2 years. For allocation
of each subject to a treatment arm a centralized elec-
tronic randomization system will be used. Hospital visits
will take place at 4, 16 and 24 weeks, and for long-term
follow-up after 1 year and 2 years. Additionally, patients
will be asked to perform weekly home spirometry and
record symptoms and side-effects via a home monitoring
application for 24 weeks.
Hospital visits
Baseline characteristics of patients, such as gender, age,
self-reported ethnicity, smoking status, comorbidity, co-
medication, date of sarcoidosis diagnosis, details of
organ involvement, and if available details of x-ray and
chest CT scan will be recorded. At every visit, a physical
examination will be performed to record weight, height,
waist circumference and blood pressure of the patients.
In-hospital pulmonary function measurements will in-
clude FVC, Forced Expiratory Volume in 1 second
(FEV1) and diffusion capacity of the lung for carbon
monoxide (DLCOc). Furthermore, routine blood sam-
ples will be collected to assess blood count, kidney- and
Table 1 Endpoints of the PREDMETH study listed as primary
endpoint, secondary endpoints and explorative endpoints
Primary endpoint
- Between-group difference in change in hospital-measured Forced
Vital Capacity (FVC) % predicted between baseline and 24 weeks
Secondary endpoints
- Difference in change in FVC % predicted at 4, 16 weeks, 1 year and
2 years between prednisone and methotrexate group
- Time to major pulmonary improvement measured by home-
measured FVC, whereby major pulmonary improvement is defined as
80% of the maximum percent predicted FVC reached anywhere dur-
ing the first 24 weeks of treatment
- The percentage of patients with ≥5 and≥ 10% improvement or
decline in FVC at 4, 16 and 24 weeks
- The percentage of patients with ≥10% improvement or decline in
DLCO at 4, 16 and 24 weeks
- Change over time in (Health-related) quality of life measured by
King’s Sarcoidosis Questionnaire (KSQ), Global Rating of Change scale
(GRoC), Chronic Respiratory Questionnaire (CRQ) and Euroqol-5D-5L
questionnaire (EQ-5D-5L) at every clinical visit
- Time to symptom improvement. Symptom scores measured by
Visual Analogue Scales (VAS), Medical Research Council dyspnea scale
(MRC) and Fatigue Assessment Scale (FAS)
- Expectations with medication at baseline
- Experiences and satisfaction with medication measured by the
Patient Experience and Satisfaction with Medication Questionnaire
(PESaM)
- Number, severity and impact of side-effects compared between
methotrexate and prednisone
- Number of patients who discontinue/switch medication
- Adherence to treatment schedule (% of patients that received at
least 90% of the total cumulative dose after 24 weeks).
- Correlation between angiotensin coverting enzyme (ACE), serum
soluble interleukin-2 receptor (sIL-2R) and clinical parameters
Explorative endpoints
- Asses predictors of disease progression and response to therapy
- Correlations between biomarker characteristics and clinical
parameters
- Change in biomarkers over time
- Explore potential differences in distribution/phenotypes of
monocytes, Th-cells, dendritic cells and new biomarkers identified
using proteomics between patients during treatment with prednisone
or methotrexate at all points
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liver function. An additional sample of 80 ml blood will
be taken for analysis of Angiotensin coverting enzyme
(ACE), Serum soluble interleukin-2 receptor (sIL-2R),
monocyte subsets, T-cells, dendritic cells, and proteo-
mics biomarker discovery. Patients will also be asked to
complete patient-reported outcome measures (PROMs)
via a home monitoring app at every visit. The PROMs
consist of the Fatigue Assessment Scale (FAS), the King’s
Sarcoidosis Questionnaire (KSQ), Global Rating of
Change Scale (GRoC), Chronic Respiratory Question-
naire (CRQ), Patient Experience and Satisfaction with
Medication Questionnaire (PESaM) and Euroqol-5D-5L
questionnaire (EQ-5D-5L). At follow-up visits all adverse
events will be evaluated and recorded. Side-effects will
be managed according to the discretion of the treating
physician. Physicians can deviate from the treatment
flowchart at any time, if the clinical situation demands
so. The study design is shown in Table 3.
Treatment schedule
For prednisone the standard dosage according to litera-
ture is 20–40 mg daily [3, 7]. Patients will start with 40
mg prednisone daily for 4 weeks. Subsequently, this dose
will be tapered to a maintenance dose of 10 mg/day
within 16 weeks. The maintenance dose will be contin-
ued until 24 weeks after start of treatment. After 24
weeks, the prednisone is either continued at 10 mg or
further reduced at the discretion of the treating phys-
ician. According to current clinical recommendations
patients will also receive calcium 500mg /colecalciferol
400 IE per day (6 days per week) and risedronic acid 35
mg once a week. In case of intolerable side-effects of
prednisone, the treating physician will start early taper-
ing. If side-effects remain intolerable, prednisone will be
discontinued and patients will start on the methotrexate
schedule.
For methotrexate, the starting dosage will be 15 mg
once a week, with folic acid 5 mg once a week. Subse-
quently, the dose will be increased to 25mg/week within
8 weeks if tolerated. After 24 weeks, the dose of metho-
trexate is either continued or reduced at the discretion
of the treating physician. Methotrexate will be discontin-
ued if aspartate aminotransferase (AST) is > 3 times the
upper limit of normal. In case of intolerable side-effects
of methotrexate the total dose will be divided in twice
weekly. If side-effects do not subside, oral methotrexate
will be switched to subcutaneous methotrexate in the
same dose. If side-effects remain intolerable, dosage of
subcutaneous methotrexate will be tapered according to
the discretion of the treating physician. If side-effects do
not subside, methotrexate will be discontinued and the
patient will start on the prednisone schedule. If an abso-
lute FVC decline of ≥10% on in-hospital measurement
of FVC is detected, the other treatment arm will be
added to the current therapy (i.e. patients on methotrex-
ate will additionally start with the prednisone schedule
and patients on prednisone will additionally start with
the methotrexate schedule). In this case, patients will be
treated with both methotrexate and prednisone and re-
main in the study. At any time, the treating physician
may decide to deviate from this treatment schedule if
the clinical situation demands so. Figure 1 shows the
treatment schedule of prednisone and methotrexate.
Home monitoring
For home monitoring of pulmonary function, symptoms
and side-effects, a home monitoring application will be
used, which has previously been developed together with
sarcoidosis patients [21]. The application will be in-
stalled on a smartphone or tablet. In this CE-marked, se-
cured application (Curavista, the Netherlands), patients
will keep track of their own data, such as pulmonary
function, side-effects and symptoms. A graphic overview
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
- Diagnosis of sarcoidosis according to the ATS/ERS/WASOG criteria [6], in
case of absent histology a diagnosis of sarcoidosis can also be
established in a multidisciplinary team meeting in a sarcoidosis expert
center based on a highly suggestive clinical and radiological picture [22]
- Age ≥ 18 years
- A pulmonary indication for treatment and parenchymal involvement on
X-ray or chest CT-scan conducted within three months before inclusion
(determined by the treating physician and according to current
guidelines)
- A forced vital capacity (FVC) of ≤90% of predicted, or a diffusion
capacity of the lung for carbon monoxide (DLCO) ≤70% of predicted, or
an absolute decline of ≥5% FVC decline, or an absolute ≥10% DLCO
decline in the past year
- Any condition or circumstance that, in the opinion of the investigator,
may make a subject unlikely or unable to complete the study or
comply with study procedures
- Previous immunosuppressive treatment for sarcoidosis
- Use of systemic immunosuppressive therapy within the preceding
three months for another disease than sarcoidosis
- Pregnant, breastfeeding, or planning to become pregnant or breastfeed
during the study treatment or within 90 days after the last dose in the
randomized study phase. For males; planning to pro-create during the
study or within 90 days after the last dose of the randomized study
phase
- Primary systemic treatment indication being an extra pulmonary
location of sarcoidosis (e.g. cardiac of neurological)
- Contra-indication for methotrexate or corticosteroidsa
aContra-indications for methotrexate or corticosteroids are defined as: severely impaired renal function (creatinine clearance < 30 ml/min), impaired hepatic
function (serum bilirubin-value > 5mg/dl or 85,5 μmol/l), bone marrow insufficiency with severe leukopenia, thrombocytopenia, or anaemia, severe acute or
chronic infections, such as tuberculosis, human immunodeficiency virus, parasitic infections or other immunodeficiency syndromes, mouth, stomach or
duodenal ulcers
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Table 3 Study schedule of the PREDMETH study
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of results is available, so patients can gain more insight
in their disease course, an example is shown in Fig. 2. A
handheld spirometer (Spirobank Smart, MIR, Italy) will
be handed out to all patients. Patients will be instructed
to undertake spirometry (three consecutive measure-
ments) once a week at the same day, at approximately
the same time to enhance compliance and reduce vari-
ability [23]. The best result of the day will be transmitted
real-time to the patients’ personal platform and will be
directly accessible for both patients and the study team.
This will enable close monitoring and early detection of
possible deterioration. On the same day as spirometry,
patients will report their symptoms and, if any, side-
effects on their personal platform. Patients record cough,
dyspnea, fatigue, and general complaints on a visual ana-
log scale (VAS) and will also report dyspnea on the
Medical Research Council scale (MRC). In case of side-
effects, patients can record which side-effects they have
and how bothersome they are. When FVC declines
≥10%, or side-effects are burdensome, an email alert will
be sent directly to the treating physician, who will con-
tact the patient within 24 h to discuss symptoms and
Fig. 1 Flow chart of the treatment schedule for methotrexate and prednisone during the randomisation phase
Fig. 2 Example of Home spirometry outcome, this graphical overview is available on patient’s personal platform and is accessible for both
patients and the study team
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decide whether an extra outpatient clinic visit with pul-
monary function measurement is needed. Further-
more, patients will be asked to complete PROMs at
every time point before the doctor’s visit.
Serum and cellular biomarkers
Blood samples will be analyzed in order to study both
serum and cellular biomarkers. With regards to serum
biomarkers, the value of existing biomarkers such as
ACE and sIL-2R in predicting disease progression or re-
sponse to therapy will be studied prospectively. Further-
more, a proteomics approach will be used to search for
possible new biomarkers in sarcoidosis. Regarding cellu-
lar biomarkers, the amount of Th17-lineage cells, DCs
and monocytes will be analyzed in order to predict re-
sponse for individual patients to prednisone and/or
methotrexate.
Sample size calculation
The power calculation is based on data from a previous
observational study with prednisone in newly treated pa-
tients with pulmonary sarcoidosis. In this study, the
mean increase in FVC with prednisone was 15%, with a
standard deviation of 10.5% [8]. In a case series of 50 pa-
tients with sarcoidosis treated with methotrexate, treat-
ment effect was in line with the findings for prednisone;
66% of patients had more than 15% improvement in vital
capacity after 6 months [24]. We chose a non-inferiority
margin of 5%, because FVC measurements show bio-
logical variation and thus variation < 5% is not consid-
ered clinically relevant. Based on these numbers, using a
one-sided test with a power of 80% (β) and a type 1
error of 5% (α), the estimated sample size of this study is
110 patients. To allow for 20% drop-out, we aim to
randomize 138 patients.
Statistical analyses
The primary analysis will be based on the Intention-to-
Treat (ITT) population, defined as all randomized pa-
tients who received at least one dose of prednisone or
methotrexate. Patients who discontinue treatment pre-
maturely will be analyzed based on the available data. As
a sensitivity analysis, a Per Protocol analysis will be per-
formed in all enrolled patients who complete the 24
week treatment regimen without major protocol viola-
tions. Change in FVC (% predicted) between baseline
and 24 weeks follow-up will be compared between the
two groups by using multilevel analysis with the re-
peated values of FVC as dependent variable and groups,
time (defined as categorical variable) and baseline FVC
as covariate. To account for the repeated FVC measure-
ments, patient will be included as a random effect. Add-
itionally the interaction terms between the time points
and group will be added to assess at which point in time
the groups have different average FVC values.
(Generalized) multilevel analyses will also be used to
evaluate within and between-group differences in pul-
monary function, symptoms, QoL scores, and side-
effects over the study period. Between-group differences
in mean time to onset of side-effects and time to symp-
tom improvement will be analyzed using Kaplan Meier
and log rank test. The Chi square test will be used to
evaluate between-group differences in the proportions of
patients who discontinue medication, proportion of pa-
tients who have FVC improvement and FVC decline,
and the proportion of patients who adhere to the treat-
ment schedule. The time to pulmonary improvement,
using home spirometry, will be assessed using a linear
mixed model, with FVC as dependent variable and time
and treatment group as independent variables. Time will
be entered as a random effect and will be modelled flex-
ible. Moreover, this model will incorporate the change
in curvature of the FVCs temporal trajectory, and thus
enable estimation of the time point at which the max-
imum improvement in lung function is reached. Correl-
ation between lung function, side-effects, QoL scores
and symptoms will be analyzed with Pearson Correlation
Coefficient. The FVC trajectory over time will be related
to the trajectory of QoL scores over time with a linear
mixed model. Logistic regression will be used to analyze
which clinical or laboratory parameters are associated
with disease progression (defined as ≥10% FVC decline)
and disease chronicity.
Discussion
There is a major unmet need for better evidence-based
treatment in sarcoidosis. Although this has already been
acknowledged in the ATS/ERS/WASOG guideline 20
years ago, research into first-line treatment options is
still lacking. This will be the first study evaluating the ef-
ficacy of methotrexate as a first-line treatment for pul-
monary sarcoidosis. As prednisone is often accompanied
by many side-effects, the possibility to choose for metho-
trexate as first-line therapy may potentially lead to a re-
duction in side-effects and improvement in quality of
life for patients. A non-inferiority design was chosen
since we hypothesize that methotrexate is as effective as
prednisone (non-inferiority margin considered), but has
fewer side-effects. We chose a non-blinded design be-
cause it would be practically impossible to integrate dos-
ing and tapering schedules as described in a double-
blind study.
Previous studies evaluated the efficacy of methotrexate
as second-line therapy and showed a steroid-sparing ef-
fect and significant increase in pulmonary function. In
these trials, dosages between 10 and 15mg methotrexate
were used [14, 15]. In the current trial, methotrexate will
Kahlmann et al. BMC Pulmonary Medicine          (2020) 20:271 Page 7 of 9
be initiated at 15 mg and, if tolerated, subsequently in-
creased until 25 mg. This treatment schedule is chosen
based on experiences with methotrexate in rheumatoid
arthritis, for which starting dosages of 15 mg/week escal-
ating with 5 mg/month to 25-30 mg/week have been
demonstrated to have the best clinical efficacy [25]. By
using an online home monitoring program, potential
side-effects will be closely monitored and where needed
medication will be adjusted. The study design and treat-
ment schedule have been developed together with a pa-
tient panel, to ensure that the burden of study
participation will be acceptable for patients.
Next to side-effects and symptoms, the home monitor-
ing program also allows for close monitoring of lung
function. A previous observational study in patients with
pulmonary sarcoidosis, newly treated with prednisone,
showed that home spirometry can reliably detect
changes in pulmonary function in sarcoidosis patients
and assess the time to pulmonary improvement [8].
The major increase in FVC already occurred within
the first month of treatment; however, until now no
consensus exists on the optimal tapering schedule [7]. The
PREDMETH trial will also provide data on time to pul-
monary improvement in patients treated with methotrex-
ate, which are currently lacking. The online home
monitoring program that will be used in the current study,
has been previously evaluated together with sarcoidosis
patients in a pilot study. This study showed that patient
satisfaction and compliance were high, and the reproduci-
bility of FVC was good [21]. Thus, home monitoring will
allow us to better evaluate (early) response to therapy,
could enable personalized tapering of medication in the
future and will provide more insights in the balance of ef-
fects and side-effects in newly-treated sarcoidosis patients.
Next to the important clinical aims of the study,
the role of serum and cellular biomarkers in disease
pathogenesis as well as predicting disease outcome
will be further explored [26]. By combining these
insights with the clinical outcomes of the study this
trial will hopefully provide unique insights in the
development and disease course of pulmonary
sarcoidosis.
In conclusion, by conducting a randomized clinical
trial to compare prednisone and methotrexate as first
line treatment of pulmonary sarcoidosis we expect to ad-
vance evidence based treatment practice for sarcoidosis.
Furthermore, seamlessly integrating translational re-
search on patient samples from this trial will provide
more insights not only with regard to tailored treatment,
but also in the pathophysiological mechanisms of sar-
coidosis. All together, we believe that the proposed study
has the potential to enhance evidence-based and person-
alized therapy that improves outcomes and quality of life
for patients with sarcoidosis.
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